The evolution of such medicines represents a long term

Bags Chloe Replica Leather is the first choice for every man when it comes to buying shoes. Men’s leather shoes are simply known for adding style and fashion statement to your personality. You can flaunt your looks and style by wearing highly classy and trendy men’s leather shoes on any occasion. http://www.replicachloehandbags.com replica chloe Bags Chloe Replica

Replica Chloe Handbags The green light from the European MedicineAgency (EMA) for Lilly and its partner Boehringer Ingelheim marks another step forward for biosimilar medicines, which are copies of biotech drugs that promise to cut the cost of treatment.Biosimilar versions of drugs such as EPO, used to boost red blood cells, and human growth hormone, for treating certain growth abnormalities, have been available for several years, while the first antibody based biosimilar, for rheumatoid arthritis, was approved in Europe last September.The evolution of such medicines represents a long term challenge to makers of complex biological drugs, which are given by injection and have been largely immune to generic competition up until now.Industry analysts expect Lilly’s version of insulin glargine to be priced significantly lower than Lantus, in order to attract patients and healthcare providers.Enrique Conterno, president of http://www.replicachloehandbags.com Lilly’s diabetes division, said his company’s product would provide “an important new option for the millions of patients in the EU who need basal insulin to help manage their diabetes.”Basal insulin is intended to provide long lasting blood sugar control between meals and at night.Because biotech drugs are made from living cells it is impossible to manufacture exact copies, as happens with simple chemical medicines, so European regulators have devised an approval process for products that are similar enough to do the job.The EMA, which announced its recommendation on Friday at the end of a monthly meeting of experts in London, said clinical studies had shown Abasria to have a comparable quality, safety and efficacy profile to Lantus.CASH COWThe positive recommendation from the agency’s Committee for Medicinal Products for Human Use (CHMP) will now go to the European Commission for final approval, but Lilly will not be able to launch immediately as Sanofi still has patent protection.With the European compound patent on Lantus set to expire in May 2015 in most markets, Deutsche Bank analyst Mark Clark said he expected Lilly to chloe replica start rolling out the drug for type 1 and type 2 diabetes from around the middle of next year.Although a challenge for Sanofi, Clark replica chloe said the financial impact of European approval of biosimilar Lantus would be limited as Europe accounted for only 14 percent of the product’s global sales of 5.7 billion euros (4.57 billion pounds) last year.Sanofi is also developing an improved successor to its long running cash cow. This follow on, Toujeo, could also be ready for launch in mid 2015 and Sanofi is expected to work hard to shift patients on to the new medicine. Lilly’s drug was previously known as LY2963016.(Editing by Kate Kelland, Sophie Hares and Pravin Char)Reuters is the news and media division of Thomson Reuters Replica Chloe Handbags.

What do you think?

This entry was posted in Projects. Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.